Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 20/20 | 0.72 |
| ▸ | PDCD1 | Q15116 | 15/20 | 0.72 |
| ▸ | PDCD1LG2 | Q9BQ51 | 5/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23949032 | 0.94 | PDCD1 (0.81) | CD274PDCD1 | |
| SCHEMBL23949775 | 0.93 | CD274 (0.70) | CD274PDCD1PDCD1LG2 | |
| SCHEMBL23949028 | 0.92 | PDCD1 (0.81) | CD274PDCD1 | |
| SCHEMBL23949640 | 0.92 | CD274 (0.84) | CD274PDCD1PDCD1LG2 | |
| SCHEMBL23949036 | 0.90 | CD274 (0.60) | CD274PDCD1PDCD1LG2 | |
| SCHEMBL21507206 | 0.84 | PDCD1LG2 (1.00) | CD274PDCD1LG2 | |
| SCHEMBL21618892 | 0.84 | PDCD1 (1.00) | CD274PDCD1 | |
| SCHEMBL23948916 | 0.84 | CD274 (0.76) | CD274PDCD1PDCD1LG2 | |
| SCHEMBL23949714 | 0.84 | CD274 (0.54) | CD274PDCD1PDCD1LG2 | |
| SCHEMBL21618683 | 0.84 | PDCD1 (1.00) | CD274PDCD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4026835-A2 | PD-1/PD-L1 INHIBITORS | Gilead Sciences, Inc. (US) | 2022-07-13 | — | — | EP | disclosed |
| EP-3612525-B1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES INC (US) | 2021-10-27 | — | — | EP | disclosed |
| US-20210323922-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323922-A1 | PD-1/PD-L1 INHIBITORS | CD274, PDCD1, PDCD1LG2 | CD274 1/4885PDCD1 2/4885PDCD1LG2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.